JP2017527582A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527582A5
JP2017527582A5 JP2017513488A JP2017513488A JP2017527582A5 JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5 JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017513488 A JP2017513488 A JP 2017513488A JP 2017527582 A5 JP2017527582 A5 JP 2017527582A5
Authority
JP
Japan
Prior art keywords
lif
pharmaceutical composition
agent
composition according
antagonizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049461 external-priority patent/WO2016040657A1/en
Publication of JP2017527582A publication Critical patent/JP2017527582A/ja
Publication of JP2017527582A5 publication Critical patent/JP2017527582A5/ja
Pending legal-status Critical Current

Links

JP2017513488A 2014-09-10 2015-09-10 K−Rasによって媒介されるシグナリング経路および悪性疾患の抗hLIF抗体によるターゲティング方法 Pending JP2017527582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048770P 2014-09-10 2014-09-10
US62/048,770 2014-09-10
PCT/US2015/049461 WO2016040657A1 (en) 2014-09-10 2015-09-10 TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2017527582A JP2017527582A (ja) 2017-09-21
JP2017527582A5 true JP2017527582A5 (enExample) 2018-10-18

Family

ID=55459579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513488A Pending JP2017527582A (ja) 2014-09-10 2015-09-10 K−Rasによって媒介されるシグナリング経路および悪性疾患の抗hLIF抗体によるターゲティング方法

Country Status (7)

Country Link
US (1) US20170247446A1 (enExample)
EP (1) EP3191129A4 (enExample)
JP (1) JP2017527582A (enExample)
CN (1) CN106687134A (enExample)
AU (1) AU2015314980A1 (enExample)
CA (1) CA2958685A1 (enExample)
WO (1) WO2016040657A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
CN109069211B (zh) 2016-01-26 2022-04-29 网络牙科(美国)公司 自动牙科治疗系统
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
CN112585164A (zh) * 2018-04-12 2021-03-30 免疫医疗有限公司 用于治疗癌症的、lif抑制剂和pd-1轴抑制剂的组合
CN112384166A (zh) 2018-05-10 2021-02-19 网络牙科(美国)公司 自动牙钻
WO2019220204A2 (en) * 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof
SG11202012576QA (en) * 2018-06-18 2021-01-28 Medimmune Ltd Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
JP7770924B2 (ja) * 2019-04-24 2025-11-17 メモリアル スローン ケタリング キャンサー センター Ras変異体癌を治療するための組成物および方法
WO2022051516A1 (en) 2020-09-03 2022-03-10 Cyberdontics (Usa), Inc. Method and apparatus for cna analysis of tooth anatomy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US9617336B2 (en) * 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
US20160237158A1 (en) * 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis

Similar Documents

Publication Publication Date Title
JP2017527582A5 (enExample)
Mei et al. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
JP2007526455A5 (enExample)
JP2017517520A5 (enExample)
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
JP2015532292A5 (enExample)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
JP2017537070A5 (enExample)
NZ739902A (en) Multiligand agent for drug delivery
JP2013173775A5 (enExample)
JP2013520442A5 (enExample)
JP2016528217A5 (enExample)
JP2017533222A5 (enExample)
JP2016525097A5 (enExample)
JP2019506392A5 (enExample)
JP2019533651A5 (enExample)
JP2019532047A5 (enExample)
JP2018522028A5 (enExample)
JP2013541586A5 (enExample)
Sgambato et al. Medical treatment of small cell lung cancer: state of the art and new development
JP2021501150A5 (enExample)
JP2016533373A5 (enExample)
JP2017513902A5 (enExample)
JP2017516827A5 (enExample)